History
This project evolved from an earlier Genome Canada Applied Human Health (AHH) project entitled “Mass Spectrometer-based Flow Cytometer, Methods and Applications”. Led by Dr. John E. Dick at the University Health Network, the AHH project lasted from 2005 to early 2008.
The purpose of the AHH project was to develop a technology for personalized therapeutic diagnosis and prognosis. The effort concentrated on:
-
Developing a Phase 0 prototype instrument that addresses a real diagnostic challenge
-
Developing metal-containing affinity reagents for use with the instrument
- Demonstrating how diagnostic and prognostic assessment of leukemia could be transformed
The current Genome Canada Technology Development project, entitled "Massively Multiparametric Mass Cytometer Analyzer", is led by Dr. Scott D. Tanner and is based at the University of Toronto. It is focused on pre-commercial development of the mass cytometer and reagents.
Please click here to go to the AHH project website.
This project is funded by Genome Canada through the Ontario Genomics Institute:
Complementary funding is gratefully acknowledged from:

